These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38572536)

  • 1. Prognostic Roles of Inflammatory Biomarkers in Radioiodine-Refractory Thyroid Cancer Treated with Lenvatinib.
    Kim CA; Kim M; Jin M; Kim HK; Jeon MJ; Lim DJ; Kim BH; Kang HC; Kim WB; Shin DY; Kim WG
    Endocrinol Metab (Seoul); 2024 Apr; 39(2):334-343. PubMed ID: 38572536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory biomarkers predict outcomes of patients with radioactive iodine refractory thyroid cancer treated with sorafenib.
    Jin M; Kim M; Jeon MJ; Kim EY; Shin DY; Kim BH; Kim WB; Shong YK; Lim DJ; Kim WG
    Endocrine; 2023 Aug; 81(2):298-305. PubMed ID: 36928602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib.
    Taylor MH; Takahashi S; Capdevila J; Tahara M; Leboulleux S; Kiyota N; Dutcus CE; Xie R; Robinson B; Sherman S; Habra MA; Elisei R; Wirth LJ
    Thyroid; 2021 Aug; 31(8):1226-1234. PubMed ID: 33637020
    [No Abstract]   [Full Text] [Related]  

  • 4. Sequential Analysis of Neutrophil-to-lymphocyte Ratio for Differentiated Thyroid Cancer Patients Treated With Lenvatinib.
    Fukuda N; Wang X; Ohmoto A; Urasaki T; Sato Y; Nakano K; Nishizawa M; Yunokawa M; Ono M; Tomomatsu J; Takahashi S
    In Vivo; 2020; 34(2):709-714. PubMed ID: 32111774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea.
    Song E; Kim M; Kim EY; Kim BH; Shin DY; Kang HC; Ahn BC; Kim WB; Shong YK; Jeon MJ; Lim DJ
    Thyroid; 2020 May; 30(5):732-738. PubMed ID: 31910091
    [No Abstract]   [Full Text] [Related]  

  • 6. Prognostic value of inflammatory markers NLR, PLR, and LMR in gastric cancer patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review.
    Tan S; Zheng Q; Zhang W; Zhou M; Xia C; Feng W
    Front Immunol; 2024; 15():1408700. PubMed ID: 39050856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
    Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG
    Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739
    [No Abstract]   [Full Text] [Related]  

  • 8. Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial.
    Kiyota N; Robinson B; Shah M; Hoff AO; Taylor MH; Li D; Dutcus CE; Lee EK; Kim SB; Tahara M
    Thyroid; 2017 Sep; 27(9):1135-1141. PubMed ID: 28665259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lesion-Based Evaluation Predicts Treatment Response to Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Korean Multicenter Retrospective Study.
    Lee EK; Kim SM; Kim BH; Kim MJ; Lim DJ; Kim MH; Shin DY; Kang HC; Ahn BC; Kim SW; Ahn HY; Park YJ
    Thyroid; 2019 Dec; 29(12):1811-1819. PubMed ID: 31482759
    [No Abstract]   [Full Text] [Related]  

  • 10. Prognostic role of the lymphocyte-to-monocyte ratio for clinical outcomes of patients with progressive radioiodine-refractory differentiated thyroid carcinoma treated by sorafenib.
    Ahn J; Song E; Kim WG; Kim TY; Kim WB; Shong YK; Jeon MJ
    Clin Endocrinol (Oxf); 2020 Jan; 92(1):71-76. PubMed ID: 31663136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy.
    Locati LD; Piovesan A; Durante C; Bregni M; Castagna MG; Zovato S; Giusti M; Ibrahim T; Puxeddu E; Fedele G; Pellegriti G; Rinaldi G; Giuffrida D; Verderame F; Bertolini F; Bergamini C; Nervo A; Grani G; Rizzati S; Morelli S; Puliafito I; Elisei R
    Eur J Cancer; 2019 Sep; 118():35-40. PubMed ID: 31299580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial.
    Kiyota N; Tahara M; Robinson B; Schlumberger M; Sherman SI; Leboulleux S; Lee EK; Suzuki T; Ren M; Fushimi K; Wirth LJ
    Cancer; 2022 Jun; 128(12):2281-2287. PubMed ID: 35380178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer.
    Tahara M; Kiyota N; Hoff AO; Badiu C; Owonikoko TK; Dutcus CE; Suzuki T; Ren M; Wirth LJ
    Eur J Cancer; 2021 Apr; 147():51-57. PubMed ID: 33611104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer.
    Koehler VF; Berg E; Adam P; Weber GL; Pfestroff A; Luster M; Kutsch JM; Lapa C; Sandner B; Rayes N; Fuss CT; Kreissl MC; Hoster E; Allelein S; Schott M; Todica A; Fassnacht M; Kroiss M; Spitzweg C
    Thyroid; 2021 Oct; 31(10):1531-1541. PubMed ID: 34405734
    [No Abstract]   [Full Text] [Related]  

  • 15. Baseline Tumour Size as a Prognostic Factor for Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib.
    Fukuda N; Toda K; Ohmoto A; Wang X; Hayashi N; Urasaki T; Sato Y; Nakano K; Ono M; Tomomatsu J; Mitani H; Takahashi S
    Anticancer Res; 2021 Mar; 41(3):1683-1691. PubMed ID: 33788766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial.
    Brose MS; Worden FP; Newbold KL; Guo M; Hurria A
    J Clin Oncol; 2017 Aug; 35(23):2692-2699. PubMed ID: 28613956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid.
    Tahara M; Schlumberger M; Elisei R; Habra MA; Kiyota N; Paschke R; Dutcus CE; Hihara T; McGrath S; Matijevic M; Kadowaki T; Funahashi Y; Sherman SI
    Eur J Cancer; 2017 Apr; 75():213-221. PubMed ID: 28237867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.
    Cabanillas ME; Schlumberger M; Jarzab B; Martins RG; Pacini F; Robinson B; McCaffrey JC; Shah MH; Bodenner DL; Topliss D; Andresen C; O'Brien JP; Ren M; Funahashi Y; Allison R; Elisei R; Newbold K; Licitra LF; Sherman SI; Ball DW
    Cancer; 2015 Aug; 121(16):2749-56. PubMed ID: 25913680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States.
    Kish JK; Chatterjee D; Wan Y; Yu HT; Liassou D; Feinberg BA
    Adv Ther; 2020 Jun; 37(6):2841-2852. PubMed ID: 32382946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploratory analysis of prognostic factors for lenvatinib in radioiodine-refractory differentiated thyroid cancer.
    Suzuki C; Kiyota N; Imamura Y; Goto H; Suto H; Chayahara N; Toyoda M; Ito Y; Miya A; Miyauchi A; Otsuki N; Nibu KI; Minami H
    Head Neck; 2019 Sep; 41(9):3023-3032. PubMed ID: 31013380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.